J&J leads phar­ma com­pa­nies in brand rank­ings, top­ping Roche, Bay­er and Pfiz­er amid over­all in­dus­try de­cline

John­son & John­son held on to the top spot on Brand Fi­nance’s list of most valu­able phar­ma­ceu­ti­cal brands again this year, and over­took Pfiz­er for the lead in the con­sul­tan­cy’s es­ti­ma­tion of brand strength.

Over­all, how­ev­er, many phar­ma brand val­u­a­tions dipped, with six of the top 10 com­pa­nies los­ing val­ue — in­clud­ing J&J which, de­spite re­tain­ing first place for the fifth year in a row, came in at $12.76 bil­lion in brand val­ue, dip­ping 4.6% from $13.38 bil­lion in 2022. Roche and Pfiz­er fol­lowed J&J, main­tain­ing the sec­ond and third po­si­tions but los­ing brand val­ue. Roche dropped 5.5%, and Pfiz­er dropped 2.2%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER